Literature DB >> 2858278

Vecuronium kinetics and dynamics in anesthetized infants and children.

D M Fisher, K Castagnoli, R D Miller.   

Abstract

Vecuronium kinetics and dynamics were determined in five infants (3 to 11 months old) and five children (1 to 5 years old) during anesthesia with 70% nitrous oxide and 0.9 MAC halothane. Vecuronium was infused intravenously at a rate of 2.5 micrograms/kg/min while twitch tension of the adductor pollicis muscle was recorded and venous blood samples were drawn for determination of vecuronium concentrations by mass spectrometry. The elimination t1/2 was determined by linear regression of the log postdistribution concentration-time data; these values and noncompartmental techniques were used to calculate total plasma clearance (Cl), volume of distribution at steady state (Vdss), and mean residence time. The steady-state plasma concentration resulting in 50% depression of twitch tension (Cpss50) was determined by an effect compartment and a sigmoid concentration vs. paralysis model. Vdss was larger in infants (357 +/- 70 ml/kg; mean +/- SD) than in children (204 +/- 116 ml/kg), and Cl was of the same order for infants and children (5.6 +/- 1.0 and 5.9 +/- 2.4 ml/kg/min). Mean residence time was longer in infants (66.3 +/- 22.9 minutes) than in children (34.3 +/- 8.0 minutes). Cpss50 was lower in infants (57 +/- 18 ng/ml) than in children (110 +/- 28 ng/ml). The quantity of vecuronium in the body at steady state at 50% depression of twitch tension (Vdss X Cpss50) was similar in infants and children (21.2 +/- 9.9 and 19.0 +/- 3.3 micrograms/kg). During comparable nitrous oxide-halothane anesthesia, age-related changes in Vdss, Cl, and Cpss50 were much like those found for d-tubocurarine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858278     DOI: 10.1038/clpt.1985.62

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 3.  Pharmacokinetics and pharmacodynamics of rapacuronium bromide.

Authors:  William J Wight; Peter M C Wright
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

5.  Summary of the scientific literature for pain and anxiety control in dentistry. Journal literature, January-December, 1985.

Authors:  G L McAlister; C L Richardson
Journal:  Anesth Prog       Date:  1986 Sep-Oct

Review 6.  Onset of action of relaxants.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

7.  A comparison of parametric with semiparametric analysis of the concentration versus effect relationship of metocurine in dogs and pigs.

Authors:  S L Shafer; J R Varvel; G A Gronert
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

8.  Continuous vecuronium infusion for prolonged muscle relaxation in children.

Authors:  K T Fitzpatrick; G W Black; P M Crean; R K Mirakhur
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

9.  Pharmacokinetics of pipecuronium in infants, children and adults.

Authors:  E Tassonyi; J F Pittet; C N Schopfer; J C Rouge; G Gemperle; O H Wilder-Smith; D R Morel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

10.  Mivacurium infusion requirements following vecuronium: different response between adults and children.

Authors:  W Denman; N Goudsouzian
Journal:  Can J Anaesth       Date:  1995-07       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.